CHG-2022-0211

Specification Change for Kcluximab. Formulation Change for Kcluximab — minor update. Impacts 7 markets and 5 variations.

Change Number
CHG-2022-0211
Type
Specification Change
Product
Kcluximab
Status
Submitted
Owner
Carlos Mendez
Initiated
2022-08-12
Description

Formulation Change for Kcluximab — minor update

Impacted Markets (7)
BR — BrazilGB — United KingdomKR — South KoreaTW — TaiwanTR — TurkeySE — SwedenAT — Austria
Impacted Modules
3.2.P3.2.P.33.2.S4.2.1
Linked Variations (0)
Variation #TypeApplicationStatusSubmittedApproved